Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma
Toni Choueiri shared a post on X:
“Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
Authors: Justine Panian, Caiwei Zhong, Sharon H. Choi, Kristine Ly, Roxanne Quinn, Evan Ferrier, Eddy Saad, Renee Maria Saliby, Carmel Malvar, Sumanta Pal, Hedyeh Ebrahimi, Ben Tran, Evon Jude, Aly-Khan Lalani, Cristina Suarez, Guillermo De Velasco, Ravindran Kanesvaran, Martin Zarba, Elizabeth Liow, Razane El Hajj Chehade, Rana R. McKay.”
Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023